osimertinib,lazertinib,amivantamab-vmjw
oscotec,yuhan corp,astrazeneca,genmab,janssen
['lcsm,(-blcsm)', 'osimertinib', 'lazertinib', '9006']
 abstract 9006: exciting data showing ami + lazertinib showing orr 33%, mpfs 5 months in egfr pts progressing on osimertinib. could met be the bypass? #asco22 #lcsm 
Thoracic oncologist @ CU | Interested in targeted therapies and novel biomarkers | Dabble with piano, film, and skiing on the side | Alum @Penn & @KeckMedUSC